CPRX Stock Analysis: Patent Risk Gone, Buyout Caps the Upside

CPRX stock analysis looks very different now than it did six weeks ago. The old bear case was simple: Catalyst Pharmaceuticals could lose the FIRDAPSE patent fight in May and the whole thesis would crack. That risk is gone. On May 7, Catalyst settled the last FIRDAPSE patent case with Hetero, pushing potential generic entry to January 2035. On that same day, Angelini Pharma agreed to buy Catalyst for $4.1 billion.

That means investors are no longer asking whether Catalyst is fundamentally cheap. The market already answered that. The real question is whether CPRX still offers enough upside from here, or whether the easy money has already been made.

The answer: Catalyst still looks like a very good business, but it no longer looks like a fresh asymmetric stock idea after the merger announcement.

What changed since our last CPRX stock analysis

When we last covered Catalyst Pharmaceuticals, the setup was attractive because the market was discounting a real legal overhang. The company had just posted a huge Q4 beat, guided for another year of growth, and still traded like investors expected something to go wrong.

Then two things happened.

First, Catalyst announced a settlement with Hetero covering FIRDAPSE patent litigation. Hetero can launch a generic version no earlier than January 2035, assuming FDA approval and standard conditions. Catalyst also said it has no other FIRDAPSE patent litigation pending. That matters because FIRDAPSE is still the core profit engine.

Second, Angelini Pharma agreed to acquire Catalyst for $4.1 billion. Reuters and Angelini both described the deal as Angelini’s entry into the U.S. rare disease market. For existing shareholders, that puts a ceiling on the remaining upside unless another bidder shows up.

So the CPRX debate is not about survival anymore. It is about merger math.

The business is still strong

Catalyst’s first-quarter 2026 numbers were good enough to stand on their own.

According to the company’s May 11 release:

Total Q1 2026 revenue was $149.4 million, up from $141.4 million last year.
FIRDAPSE revenue was $98.9 million, up 18.1% year over year.
AGAMREE revenue was $36.7 million, up 66.6% year over year.
GAAP net income was $63.7 million, up 12.3%.
Non-GAAP net income was $100.3 million.
Cash and cash equivalents reached $755.9 million.
The company still had no funded debt.

That is not the profile of a struggling small-cap biotech. It is a commercial rare-disease company throwing off real cash.

FIRDAPSE remains the anchor. It treats Lambert-Eaton myasthenic syndrome, a rare autoimmune disease. AGAMREE is the second growth engine, aimed at Duchenne muscular dystrophy. FYCOMPA is shrinking after loss of exclusivity, but the two promoted products are more than offsetting that decline.

There was also an important margin tailwind buried in the Q1 release. Catalyst said the royalty burden on net U.S. sales of FIRDAPSE dropped materially after the expiration of a prior upstream royalty. The overall royalty rate on net U.S. FIRDAPSE sales fell to 6%, down from a previous maximum rate of 18.5%. That is a real earnings-quality improvement, not a cosmetic adjustment.

Valuation: cheap on fundamentals, mostly capped by the deal

On pure operating metrics, Catalyst was not expensive.

CompaniesMarketCap put CPRX around a $3.81 billion market cap as of May 2026. Angelini’s announced purchase price is $4.1 billion. That gap is not huge. It tells you the market quickly repriced the stock once the overhang disappeared and the buyer showed up. Earlier this year, CPRX looked cheap on forward earnings. After the deal, straight P/E work matters less than simple takeout math.

This is where the stock changes categories.

Before May 7, CPRX was a high-conviction small-cap analysis idea. After May 7, it became more of a merger-arbitrage or event-driven situation. If the deal closes cleanly, upside is mostly the spread between the current trading price and the agreed acquisition price. If the deal breaks, the stock probably falls back toward a stand-alone valuation, though that stand-alone valuation is now stronger because the patent fight is settled.

That creates a very different risk-reward profile than the one we originally liked.

Why the patent settlement matters so much

The Hetero settlement is the real fundamental unlock here.

Catalyst said Hetero cannot market generic FIRDAPSE in the United States earlier than a specified date in January 2035. The scheduled May 18 trial is gone. Catalyst also said this resolves all pending patent litigation relating to FIRDAPSE.

That takes the most obvious short thesis off the table.

Before the settlement, skeptics could argue that CPRX was a one-product story with a court date hanging over it. Now the debate is narrower:

Can FIRDAPSE keep growing double digits from here?
How big can AGAMREE get?
Does management use the balance sheet well if the deal somehow fails?

Those are much better questions for bulls to be dealing with.

The bear case did not disappear, it just changed

There are still real risks.

The first is concentration. FIRDAPSE remains the core asset. Even with litigation settled, Catalyst is still heavily reliant on one franchise for the bulk of its earnings power.

The second is deal risk. Angelini announced the acquisition, but announced deals are not closed deals. Investors need the usual approvals and process steps to go right. If something derails the transaction, the stock likely resets lower, though probably not back to the pre-settlement panic zone.

The third is capped upside. This is the big one. If you are a small-cap investor looking for a double, CPRX is probably no longer your stock. Angelini already did the rerating for you.

The fourth is growth normalization. FIRDAPSE grew 18.1% in Q1 and AGAMREE grew 66.6%. Those are strong numbers. They are also hard numbers to sustain forever in rare disease. Great businesses still hit maturity.

The bull case is straightforward. Catalyst is a profitable rare-disease company with nearly $756 million in cash, no funded debt, improving royalty economics, a protected FIRDAPSE runway into 2035, and a signed $4.1 billion deal. If the merger closes on schedule, investors likely pick up the remaining spread with relatively limited business-risk drama.

The bear case is also straightforward. Most of the upside is already spoken for. The company may still be fundamentally attractive, but the stock is no longer mispriced in the same way. If the acquisition closes, gains are capped. If it breaks, the market will have to rediscover what stand-alone CPRX is worth in a more volatile tape.

Verdict

CPRX stock analysis in mid-May 2026 comes down to one sentence: the business improved, but the stock became less interesting.

I still like Catalyst as a company. Q1 was solid. The patent settlement was a huge win. The balance sheet is excellent. If Angelini had not shown up, I would be more bullish on the stock today than I was in March.

But Angelini did show up. That matters.

So here is the practical take: CPRX is no longer a fresh high-upside small-cap idea. It is now an event-driven hold with limited remaining upside unless a competing bidder appears or the market starts pricing a meaningfully better deal outcome.

For investors who already owned it before May 7, nice work. That was the payoff. For new money, I would not chase it as a core growth idea at this stage.

Sources

Catalyst Pharmaceuticals Q1 2026 financial results release, May 11, 2026
Catalyst Pharmaceuticals FIRDAPSE patent settlement announcement, May 7, 2026
Angelini Pharma acquisition announcement, May 7, 2026
Reuters coverage of the Angelini-Catalyst deal, May 7, 2026

This article is for informational purposes only and does not constitute financial advice. Always do your own research and consider consulting with a financial advisor before making investment decisions.